ReviewJournal of clinical medicine2022
Colistin Monotherapy versus Colistin plus Meropenem Combination Therapy for the Treatment of Multidrug-Resistant
Review in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- Colistin-based combination therapy versus monotherapy for carbapenem-resistant gram-negative bacterial infections: a systematic review and meta-analysis.Frontiers in cellular and infection microbiology · 2025Pooled it
- In Vitro Evaluation of Colistin-Meropenem Activity Against XDR and PDR Carbapenemase-ProducingPathogens (Basel, Switzerland) · 2026Article
- Treating Extensively Drug-ResistantPathogens (Basel, Switzerland) · 2026Review
- Epidemiology of Carbapenem-ResistantJournal of clinical medicine · 2026Article
- Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2025Review
- Prevalence and Resistance Profiles ofAntibiotics (Basel, Switzerland) · 2025Review
- Mathematical modelling of synergistic triple-antibiotic therapy against carbapenem-resistantJournal of medical microbiology · 2025Article
- Effect of Meropenem, Sulbactam, and Colistin Combinations on Resistance Gene Expression in Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2025Article
- A new bactericidal chlorinated derivative containing 2-aminooxazole potentiates antibacterial action of colistin against multidrug-resistant acinetobacter baumannii.Medical microbiology and immunology · 2025Article
- Risk Factors for Mortality in Patients Treated with Colistin Monotherapy for Carbapenem-ResistantInfectious diseases & clinical microbiology · 2025Article
- Mortality and clinical outcomes of colistin versus colistin-based combination therapy for infections caused by Multidrug-resistant Acinetobacter baumannii in critically ill patients.BMC infectious diseases · 2025Observational
- Flash optimization of drug combinations for Acinetobacter baumannii with IDentif.AI-AMR.npj antimicrobials and resistance · 2025Article
- Microbiome-derived antimicrobial peptides show therapeutic activity against the critically important priority pathogen, Acinetobacter baumannii.NPJ biofilms and microbiomes · 2024Article
- Article
- Treatment Strategies of Colistin ResistanceAntibiotics (Basel, Switzerland) · 2024Review
- TacklingJournal of clinical medicine · 2023Article
- Moving toward Extensively Drug-Resistant: Four-Year Antimicrobial Resistance Trends ofAntibiotics (Basel, Switzerland) · 2023Article
- Meropenem in combination with baicalein exhibits synergism against extensively drug resistant and pan-drug-resistant Acinetobacter baumannii clinical isolates in vitro.Pathogens and disease · 2023Article
- Treatment effectiveness of antibiotic therapy in Veterans with multidrug-resistantAntimicrobial stewardship & healthcare epidemiology : ASHE · 2023Article
- Reply to Daitch et al. Comment on "Huang et al. Colistin Monotherapy versus Colistin plus Meropenem Combination Therapy for the Treatment of Multidrug-ResistantJournal of clinical medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
(1) Introduction: Colistin combination therapy with other antibiotics is a way to enhance colistin activity. The purpose of this meta-analysis was to compare the efficacy and safety of treatment with colistin monotherapy versus colistin plus meropenem combination therapy in patients with drug-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.